Mifepristone ruling: biotech leaders defend FDA's autonomy and authority

Advocacy
Written By Ryan Crane

400+ biotech and pharma executives voice support for the FDA's indispensable role in regulating new medicines. The letter warns that judicial orders undermining the decisions of the FDA would destroy the basic infrastructure necessary for continued medical innovation.

Ryan Crane
Previous

Public Comment: Protect patients when implementing the price setting provisions of the Inflation Reduction Act
Next

Public Comment: Exemptions of the Inflation Reduction Act fail to provide adequate protections